Health2Sync, a Taiwan-headquartered company that offers a diabetes tracking service, has closed a $6 million Series B round aimed at expanding its business in Japan and other markets in Asia.
Carmot Therapeutics, (Berkeley, CA) announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas.
Gilead Sciences, Inc. GILD and its newly acquired cell therapy subsidiary -Kite Pharma- announced that they have inked an agreement to acquire Cell Design Labs, Inc. for $567 million. Gilead will also acquire 12.2% of Cell Design shares which are owned by Kite Pharma.
Medical researchers are increasingly turning to mobile devices such as smartphones and watches as a way to monitor patients in trials, an approach they hope improves participation and accuracy but that also has limitations.
electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, has announced it completed its Series B financing that has brought in just over $70 million of capital to the company.
AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program.
The idea of personalised seizure prediction for epilepsy is closer to becoming a reality thanks to new research published today by the University of Melbourne and IBM Research-Australia.
Three-dimensional neural circuit "asteroid" composed of neurons (blue) and astrocytes (red and green) generated from human pluripotent stem cells.
Diphtheria is rapidly spreading among Rohingya refugees in Cox’s Bazar, Bangladesh, WHO warned today.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.